Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Hepatitis C

In brief

The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.

Key facts

Study ID

NCT01856426

Run by

Enanta Pharmaceuticals, Inc

People needed

28

Starts

2013-06-01

Expected to finish

2015-10-01

Last updated by the study team

2016-01-29

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA ≥ 105 IU/mL at the time of screening.
• Subjects must have chronic HCV infection as determined by any of the following:
• be anti-HCV (+) for at least 6 months per subject history or medical records
• an anti-HCV test, viral load, or genotype > 6 months ago
• In the setting of a recent positive anti-HCV test (< 6 months), liver biopsy demonstrating chronicity
• Subjects must have IL-28b genotype "CC"
• Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2. BMI = Body weight (kg) / [Height (m)]2

You may not qualify if…

• Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days (for small molecules) whichever is longer; or longer if required by local regulations.
• Previous treatment, including the use of any investigational agents, for the treatment of HCV infection.
• Women of child bearing potential.
• Subjects with IL-28b genotype "CT or TT".
• ALT γ-GT, and AST must be below 5 x the upper limit of normal (ULN).
• Serum bilirubin must not exceed ULN.
• The PT (INR) must be within normal limits.
• If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to randomization, to rule out any laboratory error.
• Use of drugs that inhibit or induce CYP3A4.

Where it is running

• Investigative Site — Miami, Florida, United States
• Investigative Site — San Antonio, Texas, United States
• Investigative Site — Murray, Utah, United States
• Investigative Site — Frankfurt, Germany
• Investigative Site — Hamburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.